Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures

Breast Cancer Research and Treatment

Volumn 135, Issue 2, 2012, Pages 415-432

  Kabos, Peter ^a   Finlay Schultz, Jessica ^a   Li, Chunling ^a   Kline, Enos ^a   Finlayson, Christina ^b   Wisell, Joshua ^a   Manuel, Christopher A ^a   Edgerton, Susan M ^a   Harrell, J Chuck ^c   Elias, Anthony ^a   Sartorius, Carol A ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Breast cancer; Cancer testis antigens; Estrogen receptors; Gene regulation; Progesterone receptors; Tamoxifen; Xenografts

Indexed keywords

ANDROGEN RECEPTOR; ESTROGEN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TAMOXIFEN; TRANSCRIPTOME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER MODEL; CANCER PATIENT; CANCER STEM CELL; CANCER THERAPY; CONTROLLED STUDY; ESTROGEN WITHDRAWAL TREATMENT; FEMALE; GENE; GENE CONTROL; GENE EXPRESSION PROFILING; GENE MAPPING; GENE TARGETING; GENETIC CONSERVATION; GENETIC HETEROGENEITY; GENETIC TRANSCRIPTION; METASTASIS POTENTIAL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TESTIS ANTIGEN 45 GENE; TISSUE SECTION; TREATMENT RESPONSE; TUMOR GENE; TUMOR XENOGRAFT;

ANIMALS; ANTIGENS, CD24; ANTIGENS, CD44; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; CLUSTER ANALYSIS; ESTROGENS; FEMALE; GENE REGULATORY NETWORKS; HUMANS; MALE; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASMS, HORMONE-DEPENDENT; NEOPLASTIC STEM CELLS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SIGNAL TRANSDUCTION; TAMOXIFEN; TRANSCRIPTOME; TUMOR BURDEN; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84866557855     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-2164-8     Document Type: Article

References (64)

1. Obiorah I, Jordan VC (2011) Progress in endocrine approaches to the treatment and prevention of breast cancer. Maturitas 70(4):315-321. doi:10.1016/j.maturitas.2011.09.006
2. Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM (2003) Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 21(10):1973-1979. doi:10.1200/JCO.2003.09.099 (Pubitemid 46606386)
3. Axlund SD, Sartorius CA (2012) Progesterone regulation of stem and progenitor cells in normal and malignant breast. Mol Cell Endocrinol 357(1-2):71-79. doi:10.1016/j.mce.2011.09.021
4. Moinfar F, Okcu M, Tsybrovskyy O, Regitnig P, Lax SF, Weybora W, Ratschek M, Tavassoli FA, Denk H (2003) Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies. Cancer 98(4):703-711. doi:10.1002/cncr.11532 (Pubitemid 36959265)
5. Gonzalez LO, Corte MD, Vazquez J, Junquera S, Sanchez R, Alvarez AC, Rodriguez JC, Lamelas ML, Vizoso FJ (2008) Androgen receptor expression in breast cancer: relationship with clinicopathological characteristics of the tumors, prognosis, and expression of metalloproteases and their inhibitors. BMC Cancer 8:149. doi:10.1186/1471-2407-8-149 (Pubitemid 351803890)
6. Peters AA, Buchanan G, Ricciardelli C, Bianco-Miotto T, Centenera MM, Harris JM, Jindal S, Segara D, Jia L, Moore NL, Henshall SM, Birrell SN, Coetzee GA, Sutherland RL, Butler LM, Tilley WD (2009) Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. Cancer Res 69(15):6131-6140. doi:10.1158/0008-5472.CAN-09-0452
7. Farmer P, Bonnefoi H, Becette V, Tubiana-Hulin M, Fumoleau P, Larsimont D, Macgrogan G, Bergh J, Cameron D, Goldstein D, Duss S, Nicoulaz AL, Brisken C, Fiche M, Delorenzi M, Iggo R (2005) Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 24(29):4660-4671. doi:10.1038/ sj.onc.1208561 (Pubitemid 41032603)
8. Guedj M, Marisa L, de Reynies A, Orsetti B, Schiappa R, Bibeau F, Macgrogan G, Lerebours F, Finetti P, Longy M, Bertheau P, Bertrand F, Bonnet F, Martin AL, Feugeas JP, Bieche I, Lehmann-Che J, Lidereau R, Birnbaum D, Bertucci F, de The H, Theillet C (2011) A refined molecular taxonomy of breast cancer. Oncogene. doi:10.1038/onc.2011.301
9. Prat A, Perou CM (2011) Deconstructing the molecular portraits of breast cancer. Mol Oncol 5(1):5-23. doi:10.1016/j.molonc. 2010.11.003
10. Osborne CK, Schiff R (2011) Mechanisms of endocrine resistance in breast cancer. Annu Rev Med 62:233-247. doi: 10.1146/annurev-med-070909-182917
11. Abd El-Rehim DM, Pinder SE, Paish CE, Bell J, Blamey RW, Robertson JF, Nicholson RI, Ellis IO (2004) Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol 203(2):661-671. doi:10.1002/path.1559 (Pubitemid 38714103)
12. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC (2010) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28(16):2784-2795. doi:10.1200/ JCO.2009.25.6529
13. Creighton CJ, Fu X, Hennessy BT, Casa AJ, Zhang Y, Gonzalez-Angulo AM, Lluch A, Gray JW, Brown PH, Hilsenbeck SG, Osborne CK, Mills GB, Lee AV, Schiff R (2010) Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER? breast cancer. Breast Cancer Res 12(3):R40. doi:10.1186/bcr2594
14. De Amicis F, Thirugnansampanthan J, Cui Y, Selever J, Beyer A, Parra I, Weigel NL, Herynk MH, Tsimelzon A, Lewis MT, Chamness GC, Hilsenbeck SG, Ando S, Fuqua SA (2010) Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat 121(1): 1-11. doi:10.1007/s10549-009-0436-8
15. Lange CA, Yee D (2011) Killing the second messenger: targeting loss of cell cycle control in endocrine-resistant breast cancer. Endocr Relat Cancer 18(4):C19-C24. doi:10.1530/ERC-11-0112
16. O'Brien CS, Howell SJ, Farnie G, Clarke RB (2009) Resistance to endocrine therapy: are breast cancer stem cells the culprits? J Mammary Gland Biol Neoplasia 14(1):45-54. doi:10.1007/ s10911-009-9115-y
17. Honeth G, Bendahl PO, Ringner M, Saal LH, Gruvberger-Saal SK, Lovgren K, Grabau D, Ferno M, Borg A, Hegardt C (2008) The CD44+/CD24-phenotype is enriched in basal-like breast tumors. Breast Cancer Res 10(3):R53. doi:10.1186/bcr2108
18. Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P, Hur MH, Diebel ME, Monville F, Dutcher J, Brown M, Viens P, Xerri L, Bertucci F, Stassi G, Dontu G, Birnbaum D, Wicha MS (2009) Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 69(4):1302-1313. doi:10.1158/0008-5472. CAN-08-2741
19. Fillmore CM, Kuperwasser C (2008) Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res 10(2):R25. doi:10.1186/bcr1982
20. Boecker W, Moll R, Poremba C, Holland R, Van Diest PJ, Dervan P, Burger H, Wai D, Ina Diallo R, Brandt B, Herbst H, Schmidt A, Lerch MM, Buchwallow IB (2002) Common adult stem cells in the human breast give rise to glandular and myoepithelial cell lineages: a new cell biological concept. Lab Invest 82(6):737-746. doi:10.1002/path.1241 (Pubitemid 35446999)
21. Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH, Asselin-Labat ML, Gyorki DE, Ward T, Partanen A, Feleppa F, Huschtscha LI, Thorne HJ, Fox SB, Yan M, French JD, Brown MA, Smyth GK, Visvader JE, Lindeman GJ (2009) Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 15(8):907-913. doi:10.1038/nm.2000
22. Kabos P, Haughian JM, Wang X, Dye WW, Finlayson C, Elias A, Horwitz KB, Sartorius CA (2011) Cytokeratin 5 positive cells represent a steroid receptor negative and therapy resistant subpopulation in luminal breast cancers. Breast Cancer Res Treat 128(1):45-55. doi:10.1007/s10549-010-1078-6
23. Carroll JS, Meyer CA, Song J, Li W, Geistlinger TR, Eeckhoute J, Brodsky AS, Keeton EK, Fertuck KC, Hall GF, Wang Q, Bekiranov S, Sementchenko V, Fox EA, Silver PA, Gingeras TR, Liu XS, Brown M (2006) Genome-wide analysis of estrogen receptor binding sites. Nat Genet 38(11):1289-1297. doi:10. 1038/ng1901 (Pubitemid 44646291)
24. Creighton CJ, Cordero KE, Larios JM, Miller RS, Johnson MD, Chinnaiyan AM, Lippman ME, Rae JM (2006) Genes regulated by estrogen in breast tumor cells in vitro are similarly regulated in vivo in tumor xenografts and human breast tumors. Genome Biol 7(4):R28. doi:10.1186/gb-2006-7-4-r28 (Pubitemid 43871882)
25. Frasor J, Danes JM, Komm B, Chang KC, Lyttle CR, Katzenellenbogen BS (2003) Profiling of estrogen up-and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 144(10):4562-4574. doi:10.1210/en.2003-0567 (Pubitemid 37204856)
26. Creighton CJ, Massarweh S, Huang S, Tsimelzon A, Hilsenbeck SG, Osborne CK, Shou J, Malorni L, Schiff R (2008) Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts. Cancer Res 68(18):7493-7501. doi:10.1158/0008-5472.CAN- 08-1404
27. Massarweh S, Osborne CK, Creighton CJ, Qin L, Tsimelzon A, Huang S, Weiss H, Rimawi M, Schiff R (2008) Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res 68(3):826-833. doi:10.1158/0008-5472. CAN-07-2707 (Pubitemid 351206760)
28. Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, Rimm DL, Wong H, Rodriguez A, Herschkowitz JI, Fan C, Zhang X, He X, Pavlick A, Gutierrez MC, Renshaw L, Larionov AA, Faratian D, Hilsenbeck SG, Perou CM, Lewis MT, Rosen JM, Chang JC (2009) Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA 106(33):13820-13825. doi: 10.1073/pnas.0905718106
29. Harvell DM, Spoelstra NS, Singh M, McManaman JL, Finlayson C, Phang T, Trapp S, Hunter L, Dye WW, Borges VF, Elias A, Horwitz KB, Richer JK (2008) Molecular signatures of neoadjuvant endocrine therapy for breast cancer: characteristics of response or intrinsic resistance. Breast Cancer Res Treat 112(3): 475-488. doi:10.1007/s10549-008-9897-4
30. Ross-Innes CS, Stark R, Teschendorff AE, Holmes KA, Ali HR, Dunning MJ, Brown GD, Gojis O, Ellis IO, Green AR, Ali S, Chin SF, Palmieri C, Caldas C, Carroll JS (2012) Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature 481(7381):389-393. doi:10.1038/nature10 730
31. Bergamaschi A, Hjortland GO, Triulzi T, Sorlie T, Johnsen H, Ree AH, Russnes HG, Tronnes S, Maelandsmo GM, Fodstad O, Borresen-Dale AL, Engebraaten O (2009) Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models. Mol Oncol 3(5-6):469-482. doi: 10.1016/j.molonc.2009.07.003
32. Marangoni E, Vincent-Salomon A, Auger N, Degeorges A, Assayag F, de Cremoux P, de Plater L, Guyader C, De Pinieux G, Judde JG, Rebucci M, Tran-Perennou C, Sastre-Garau X, Sigal-Zafrani B, Delattre O, Dieras V, Poupon MF (2007) A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin Cancer Res 13(13):3989-3998. doi:10.1158/1078-0432.CCR- 07-0078 (Pubitemid 47037607)
33. DeRose YS, Wang G, Lin YC, Bernard PS, Buys SS, Ebbert MT, Factor R, Matsen C, Milash BA, Nelson E, Neumayer L, Randall RL, Stijleman IJ, Welm BE, Welm AL (2011) Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med 17(11):1514-1520. doi:10.1038/nm.2454
34. Sartorius CA, Shen T, Horwitz KB (2003) Progesterone receptors A and B differentially affect the growth of estrogen-dependent human breast tumor xenografts. Breast Cancer Res Treat 79(3): 287-299 (Pubitemid 36750936)
35. Sartorius CA, Harvell DM, Shen T, Horwitz KB (2005) Progestins initiate a luminal to myoepithelial switch in estrogendependent human breast tumors without altering growth. Cancer Res 65(21):9779-9788. doi:10.1158/0008-5472.CAN- 05-0505 (Pubitemid 41541455)
36. Horwitz KB, Dye WW, Harrell JC, Kabos P, Sartorius CA (2008) Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts. Proc Natl Acad Sci USA 105(15):5774-5779. doi:10.1073/pnas.0706216105 (Pubitemid 351758448)
37. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM, Bernard PS (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27(8): 1160-1167. doi:10.1200/JCO.2008.18.1370
38. Harrell JC, Prat A, Parker JS, Fan C, He X, Carey L, Anders C, Ewend M, Perou CM (2012) Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse. Breast Cancer Res Treat 132(2):523-535. doi:10.1007/s10549-011-1619-7
39. Pink JJ, Jordan VC (1996) Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines. Cancer Res 56(10):2321-2330 (Pubitemid 26154081)
40. Frasor J, Stossi F, Danes JM, Komm B, Lyttle CR, Katzenellenbogen BS (2004) Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells. Cancer Res 64(4): 1522-1533 (Pubitemid 38235626)
41. Santen RJ (1996) Long-term tamoxifen therapy: can an antagonist become an agonist? J Clin Endocrinol Metab 81(6): 2027-2029 (Pubitemid 26175921)
42. Ghosh MG, Thompson DA, Weigel RJ (2000) PDZK1 and GREB1 are estrogen-regulated genes expressed in hormoneresponsive breast cancer. Cancer Res 60(22):6367-6375
43. Rae JM, Johnson MD, Scheys JO, Cordero KE, Larios JM, Lippman ME (2005) GREB 1 is a critical regulator of hormone dependent breast cancer growth. Breast Cancer Res Treat 92(2):141-149. doi:10.1007/s10549-005-1483-4 (Pubitemid 40933578)
44. Fagan DH, Yee D (2008) Crosstalk between IGF1R and estrogen receptor signaling in breast cancer. J Mammary Gland Biol Neoplasia 13(4):423-429. doi:10.1007/s10911-008-9098-0
45. Chen YT, Ross DS, Chiu R, Zhou XK, Chen YY, Lee P, Hoda SA, Simpson AJ, Old LJ, Caballero O, Neville AM (2011) Multiple cancer/testis antigens are preferentially expressed in hormone-receptor negative and high-grade breast cancers. PLoS One 6(3):e17876. doi:10.1371/journal.pone.0017876
46. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ (2005) Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 5(8):615-625. doi:10.1038/nrc1669 (Pubitemid 41081387)
47. Muss HB, Cruz JM (1992) High-dose progestin therapy for metastatic breast cancer. Ann Oncol 3(Suppl 3):15-20
48. Mahlke M, Grill HJ, Knapstein P, Wiegand U, Pollow K (1985) Oral high-dose medroxyprogesterone acetate (MPA) treatment: cortisol/MPA serum profiles in relation to breast cancer regression. Oncology 42(3):144-149 (Pubitemid 15123073)
49. Tyson JJ, Baumann WT, Chen C, Verdugo A, Tavassoly I, Wang Y, Weiner LM, Clarke R (2011) Dynamic modelling of oestrogen signalling and cell fate in breast cancer cells. Nat Rev Cancer 11(7):523-532. doi:10.1038/nrc3081
50. Krop I, Winer EP (2012) Further progress in HER2-directed therapy. Lancet Oncol 13(1):2-3. doi:10.1016/S1470-2045(11)70 388-6
51. Osborne CK, Neven P, Dirix LY, Mackey JR, Robert J, Underhill C, Schiff R, Gutierrez C, Migliaccio I, Anagnostou VK, Rimm DL, Magill P, Sellers M (2011) Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study. Clin Cancer Res 17(5):1147-1159. doi:10.1158/1078-0432.CCR-10-1869
52. Baselga J, Campone M, Piccart M, Burris HA III, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366(6):520-529. doi:10.1056/ NEJMoa1109653
53. Wolfer A, Wittner BS, Irimia D, Flavin RJ, Lupien M, Gunawardane RN, Meyer CA, Lightcap ES, Tamayo P, Mesirov JP, Liu XS, Shioda T, Toner M, Loda M, Brown M, Brugge JS, Ramaswamy S (2010) MYC regulation of a ''poor-prognosis'' metastatic cancer cell state. Proc Natl Acad Sci USA 107(8): 3698-3703. doi:10.1073/pnas.0914203107
54. Tzivion G, Gupta VS, Kaplun L, Balan V (2006) 14-3-3 proteins as potential oncogenes. Semin Cancer Biol 16(3):203-213. doi: 10.1016/j.semcancer. 2006.03.004 (Pubitemid 43810260)
55. Asselin-Labat ML, Shackleton M, Stingl J, Vaillant F, Forrest NC, Eaves CJ, Visvader JE, Lindeman GJ (2006) Steroid hormone receptor status of mouse mammary stem cells. J Natl Cancer Inst 98(14):1011-1014. doi:10.1093/jnci/djj267 (Pubitemid 44288166)
56. Sleeman KE, Kendrick H, Robertson D, Isacke CM, Ashworth A, Smalley MJ (2007) Dissociation of estrogen receptor expression and in vivo stem cell activity in the mammary gland. J Cell Biol 176(1):19-26 (Pubitemid 46041676)
57. Haughian JM, Pinto MP, Harrell JC, Bliesner BS, Joensuu KM, Dye WW, Sartorius CA, Tan AC, Heikkila P, Perou CM, Horwitz KB (2012) Maintenance of hormone responsiveness in luminal breast cancers by suppression of Notch. Proc Natl Acad Sci USA 109(8):2742-2747. doi:10.1073/pnas.1106509108
58. Fillmore CM, Gupta PB, Rudnick JA, Caballero S, Keller PJ, Lander ES, Kuperwasser C (2010) Estrogen expands breast cancer stem-like cells through paracrine FGF/Tbx3 signaling. Proc Natl Acad Sci USA 107(50):21737-21742. doi:10.1073/ pnas.1007863107
59. Magee JA, Piskounova E, Morrison SJ (2012) Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell 21(3): 283-296. doi:10.1016/j.ccr. 2012.03.003
60. Farmer P, Bonnefoi H, Becette V, Tubiana-Hulin M, Fumoleau P, Larsimont D, MacGrogan G, Bergh J, Cameron D, Goldstein D, Duss S, Delorenzi M, Iggo R (2005) Identification of molecular apocrine breast tumours by microarray analysis. Cancer Treat Rev 31:S15
61. Chlebowski RT, Anderson GL, Gass M, Lane DS, Aragaki AK, Kuller LH, Manson JE, Stefanick ML, Ockene J, Sarto GE, Johnson KC, Wactawski-Wende J, Ravdin PM, Schenken R, Hendrix SL, Rajkovic A, Rohan TE, Yasmeen S, Prentice RL (2010) Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 304(15):1684-1692. doi:10.1001/jama.2010.1500
62. Jacobsen BM, Richer JK, Sartorius CA, Horwitz KB (2003) Expression profiling of human breast cancers and gene regulation by progesterone receptors. J Mammary Gland Biol Neoplasia 8(3):257-268 (Pubitemid 39137510)
63. Graham JD, Mote PA, Salagame U, van Dijk JH, Balleine RL, Huschtscha LI, Reddel RR, Clarke CL (2009) DNA replication licensing and progenitor numbers are increased by progesterone in normal human breast. Endocrinology 150(7):3318-3326. doi: 10.1210/en.2008-1630
64. Clarke CL, Graham JD (2012) Non-overlapping progesterone receptor cistromes contribute to cell-specific transcriptional outcomes. PLoS One 7(4):e35859. doi:10.1371/journal.pone.0035 859